Oncology - Urological
RCT: Inclusion of 18F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy in patients with prostate cancer may improve survival free from biochemical recurrence or persistence.
10 May, 2021 | 00:46h | UTC18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial – The Lancet (link to abstract – $ for full-text)
Final Survival Analysis: Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
4 May, 2021 | 08:26h | UTC
Commentary on Twitter
Just in JCO @ASCO 👉Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo👉48% reduction in risk of death with APA, HR=0.52 👇https://t.co/9ZCoXsTE6x @oncoalert @urotoday pic.twitter.com/FNBFA84DxY
— Neeraj Agarwal (@neerajaiims) April 29, 2021
AHA Scientific Statement: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormonal therapies
29 Apr, 2021 | 08:33h | UTCNews release: Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones – American Heart Association
Top Things to Know: Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System – American Heart Association
Commentaries: Hormonal Therapy for Breast and Prostate Cancer: Lessons and Opportunities – American Heart Association AND Hormonal Based Therapies in the Treatment of Breast and Prostate Cancer – balancing the risks! – American Heart Association AND Hormone Cancer Therapies Increase CV Risk: AHA Scientific Statement – TCTMD AND Closely Monitor Heart Health in Cancer Patients Who Get Hormonal Therapies: AHA – HealthDay
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review
18 Apr, 2021 | 21:16h | UTC
M-A: Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy
18 Apr, 2021 | 21:14h | UTC
RCT: Better continence after 3 months with robotic-assisted compared with laparoscopic radical prostatectomy
18 Apr, 2021 | 21:11h | UTCRobotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
Robotic-assisted Versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised, Patient-blinded Controlled Trial in Radical Prostatectomy (LAP-01)https://t.co/YenifaBnfe@doguteber @Hohenfellner pic.twitter.com/kfpQc1u0xf
— European Urology (@EUplatinum) February 11, 2021
RCT: Nivolumab plus Cabozantinib vs. Sunitinib for Advanced Renal-Cell Carcinoma
4 Mar, 2021 | 08:33h | UTCNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
M-A: Local salvage therapies after radiotherapy for prostate cancer
3 Mar, 2021 | 08:06h | UTCA Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Pleased to share the results of our "MASTER" systematic review and meta-analysis of local salvage therapies for radioreccurent PCa @EUPlatinum https://t.co/23hy1UtNm5
— Amar Kishan (@AmarUKishan) December 11, 2020
RCT: Extended vs. limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer
3 Mar, 2021 | 08:05h | UTCExtended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial – European Urology (link to abstract – $ for full-text)
Commentary: Extended pelvic lymph node dissection during RP does not appear beneficial – Urology Times
Commentary on Twitter
Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial#VisualAbstract https://t.co/7fAFlKmfTf@jeanlestingi @qdtrinh @RafaelFCoelho2 pic.twitter.com/es53WpXBFR
— European Urology (@EUplatinum) December 10, 2020
Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update
21 Feb, 2021 | 21:47h | UTC
Preliminary study suggests there may be a role for prostate cancer screening with magnetic resonance imaging
16 Feb, 2021 | 01:50h | UTCCommentaries: Short MRI Protocol Could Be Alternative for Prostate Cancer Follow-Up – Diagnostic Imaging AND Short MRI exam shows promise for prostate cancer screening follow-up – AuntMinnie (free registration required)
Commentary on Twitter
A handy infographic of our recently published research
Full paper is open access and free for all 🔬📜🙌
👉https://t.co/xDlz1A4kjR@eldredevans @JAMAOnc @EmilyD_stats @SageOfLondon1 @Connor_Urol @ImperialSandC @LondonProstate1 @Francy_lif @ProfPadhani @HemmySokhi pic.twitter.com/cEwSCv4NXy— Imperial Prostate (@IP_London) February 14, 2021
RCT: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
15 Feb, 2021 | 00:36h | UTCLenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021
RCT: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
15 Feb, 2021 | 00:34h | UTCEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
RCT: A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma
15 Feb, 2021 | 00:32h | UTCA comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Cabozantinib most effective treatment for metastatic papillary kidney cancer – MedicalXpress
Long-term data: No difference in cardiovascular mortality or morbidity with transdermal estradiol vs. LHRH agonists for androgen suppression in prostate cancer
15 Feb, 2021 | 00:31h | UTCTransdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme – The Lancet (link to abstract – $ for full-text)
RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer
15 Feb, 2021 | 00:29h | UTC[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today
RCT: MRI-targeted biopsy safely reduces the need for biopsy in more than one-third of men at risk for prostate cancer
5 Feb, 2021 | 01:27h | UTCCommentary: Clinical trial: Using MRI for prostate cancer diagnosis equals or beats current standard – Ontario Institute for Cancer Research AND Another Win for MRI and Targeted Prostate Biopsy – MedPage Today (free registration required)
Related: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis – New England Journal of Medicine (study and commentaries) Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis – European Urology AND Meta-Analysis: MRI plus Targeted Biopsy vs. Systematic Biopsy Alone for the Diagnosis of Prostate Cancer (studies and commentaries)